Take a look at our previous reports:

Evolution of Remuneration and Company Performance

The below table shows the annual change of remuneration of each Board member, the CEO and the other Executive Committee members (in aggregate), of the performance of the Company and of average remuneration on a full-time equivalent basis of Galapagos’ employees, other than members of the Board of Directors and the Executive Committee, over the five most recent financial years.

Evolution of remuneration and company performance

Comparative table of remuneration and company performance

 

2024

% change

2023

% change

2022

% change

2021

% change

2020

Director's remuneration(1)

Executive Committee(2) (3)

Stoffels IMC BV, permanently represented by Dr. Stoffels(4)

€1,222,950

-3%

€1,256,250

40%

€900,000

N/A

N/A

N/A

N/A

€2,718,034

38%

€1,971,286

34%

€1,470,000

N/A

N/A

N/A

N/A

Other Executive Committee members(4)

€1,788,000

15%

€1,557,439

N/A

N/A

N/A

N/A

N/A

N/A

€2,829,736

56%

€1,810,198

N/A

N/A

N/A

N/A

N/A

N/A

Board of Directors(5) (6)

Mr. Peter Guenter(7)

€68,338

5%

€65,000

0%

€65,000

0%

€65,000

0%

€65,000

€121,688

6%

€115,000

0%

€115,000

0%

€115,000

0%

€115,000

Dr. Elisabeth Svanberg(8)

€108,338

22%

€88,753

37%

€65,000

0%

€65,000

47%

€44,164

€161,688

17%

€138,753

21%

€115,000

0%

€115,000

47%

€77,999

Mr. Jérôme Contamine(9)

€116,690

17%

€100,000

47%

€68,131

N/A

N/A

N/A

N/A

€183,440

22%

€150,000

47%

€102,131

N/A

N/A

N/A

N/A

Dr. Dan Baker(10)

€62,775

-7%

€67,360

98%

€34,066

N/A

N/A

N/A

N/A

€102,925

-12%

€117,360

72%

€68,066

N/A

N/A

N/A

N/A

Dr. Susanne Schaffert(11)

€69,221

117%

€31,849

N/A

N/A

N/A

N/A

N/A

N/A

€122,571

105%

€59,849

N/A

N/A

N/A

N/A

N/A

N/A

Mr. Simon Sturge(12)

€79,052

330%

€18,369

N/A

N/A

N/A

N/A

N/A

N/A

€132,402

309%

€32,369

N/A

N/A

N/A

N/A

N/A

N/A

 

 

 

 

 

 

 

 

 

 

Company performance

Financial KPIs (thousand of €, except for the stock price and number of employees)

Operational Cash burn (-)/operational cash flow

-373,961

-10%

-414,824

-19%

-513,774

-9%

-564,840

9%

-517,400

R&D expenditure(13)

343,611

-20%

431,471

-16%

515,083

5%

491,707

-7%

531,354

Cash position on 31 Dec(14)

3,317,755

-10%

3,684,508

-10%

4,094,062

-13%

4,703,177

-9%

5,169,349

# of employees on 31 Dec(15)

704

-37%

1,123

-16%

1,338

2%

1,309

-12%

1,489

Stock price performance (Last trading day FY)

26.52

-28%

36.99

-11%

41.35

-16%

49.22

-39%

80.48

Average remuneration of employees on FTE basis

Employees of the Group(16)

€124,558

-1.08%

€125,920

2%

€123,958

21%

€102,471

-2%

€104,290

(1)

The Directors' remuneration overview contains for the CEO, other Executive Committee members and Directors two separate rows, whereby the first row sets out their cash remuneration, being the annual base salary, cash bonus and (if any) exceptional bonus, to enable the comparison with the average remuneration of employees on FTE basis, and the second row sets out their total remuneration, including equity-related remuneration such as granted SRs and vested RSUs.

(2)

The first row shows the cash remuneration of the CEO and the other Executive Committee members (in aggregate), being the annual base salary, cash bonus and (if any) exceptional bonus.

(3)

The second row shows the total remuneration of the CEO and the other Executive Committee members (in aggregate), including equity-based remuneration such as RSUs vested and subscription rights granted during the year. The value of the subscription rights is calculated by comparing the exercise price of the subscription right plan with the average share price as quoted on Euronext Brussels and Amsterdam during the respective financial year. For example, for financial year 2024 the exercise price of the Subscription Right Plan 2024 BE is compared with the average share price as quoted on Euronext Brussels and Amsterdam during the financial year 2024.

(4)

The other Executive Committee members during financial year 2024 are Mr. Thad Huston, Ms. Annelies Missotten, and Ms. Valeria Cnossen. Their remuneration over the five year period is included under the "Other Executive Committee members". Since all their mandates started as of financial year 2023, we only mentioned data in the above table as of financial year 2023.

(5)

The first row shows the total cash remuneration of each member of the Board of Directors, being the Board fees. This table excludes the Chair, Stoffels IMC BV, who is not remunerated for its mandate as Chair of the Board of Directors or any Committee mandate, Mr. Daniel O'Day, Mr. Andrew Dickinson and Dr. Linda Higgins, the Gilead Board representatives, and Mr. Oleg Nodelman, the Ecor1 representative, who are not remunerated for their Board or Committee mandates.

(6)

The second row shows the total remuneration of each member of the Board of Directors, including equity-based remuneration such as subscription rights granted during the year. As from January 1, 2020, Galapagos no longer grants any subscription rights to members of the Board of Directors.

(7)

Director as of April 30, 2019.

(8)

Director as of April 28, 2020.

(9)

Director as of April 26, 2022.

(10)

Director between April 26, 2022 and October 6, 2024.

(11)

Director as of June 12, 2023.

(12)

Director as of September 19, 2023.

(13)

R&D expenditure presented on this line is reflecting the total Group related expenditure including the Jyseleca business transferred to Alfasigma on January 31, 2024 presented as discontinued operations in our 2023 and 2024 consolidated financial statements, and prior to financial year 2021 also including Fidelta, our fee-for-service business sold to Selvita on January 4, 2021, classified as discontinued operations in our 2020 consolidated financial statements.

(14)

Cash position on December 31, 2023 included €7 thousands of cash held in subsidiaries transferred to Alfasigma on January 31, 2024 and classified as assets held for sale in our 2023 consolidated financial statements. Cash position on December 31, 2020 included €7,884 thousands of cash held in Fidelta and classified as assets held for sale in our 2020 consolidated financial statements.

(15)

The number of employees per December 31, 2024 and per December 31, 2023 includes employees and insourced personnel (external contractors). At December 31, 2023, the number of employees included 390 employees transferred to Alfasigma on January 31, 2024. At December 31, 2020, the number of employees included 185 employees of our fee for service activity Fidelta, which was sold to Selvita on January 4, 2021.

(16)

The average remuneration of employees is calculated on FTE basis, excluding trainees and internships, for employees employed for the full applicable financial year. It takes into account the employees' base salary, annual cash bonus and (if any) exceptional cash bonus during the respective financial year. Annual cash bonuses are included in the year upon which performance is based and not in the year in which they are paid. Due to the timing of the 2024 year-end process, the actual annual figures for employees had not been finalized by the date of this report. Therefore, 2024 annual bonus figures represent target figures multiplied by the applicable approved corporate bonus funding score, being the Company’s best estimate of actual bonus outcomes.